Key Takeaways STE's Healthcare unit saw 6% organic growth, fueled by U.S. procedures, pricing and market share gains. STERIS' AST business saw robust growth, aided by EO sterilization and demand from biopharma makers. STE cut long-term debt by 38.5%, ending fiscal Q4 with more cash than short-term debt on the books.STERIS plc’s (STE) Healthcare segment is gaining from the successful market adoption of its comprehensive offering, including infection prevention consumables and capital equipment. The Applied ...

Investor Presentation June 2025 Forward Looking Statements This presentation contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to STERIS or its industry, products or activities that are intended to qualify for the protections afforded "forward-looking statements" under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward- looking statements speak only as to the date the statemen ...

2025/6/16 15:19 Impact of tariffs on the semiconductor industry | McKinsey Semiconductors Sign In | Subscribe The effects of tariffs on the semiconductor industry May 27, 2025 | Article Given the shifting landscape, semiconductor executives could prepare their companies by determining the potential impacts of taris and exploring dierent scenarios to mitigate them. DOWNLOADS Article (14 pages) T his analysis does not constitute legal or regulatory advice; it is based solely on publicly available information. ...

STERIS' (STE) new acquisitions and partnerships strengthen its product offerings. The stock carries a Zacks Rank #2 (Buy) currently.Factors Driving STERIS' GrowthSTERIS’ Healthcare segment is gaining from the successful market adoption of its comprehensive offerings, including infection prevention consumables and capital equipment. Further, its services to maintain that equipment, repair reusable procedural instruments and outsource instrument reprocessing services are gaining traction. For the fourth quart ...

For the quarter ended March 2025, Steris (STE) reported revenue of $1.48 billion, up 4.3% over the same period last year. EPS came in at $2.74, compared to $2.41 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.48 billion, representing a surprise of -0.09%. The company delivered an EPS surprise of +5.79%, with the consensus EPS estimate being $2.59.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectati ...

Analysts on Wall Street project that Steris (STE) will announce quarterly earnings of $2.58 per share in its forthcoming report, representing an increase of 7.1% year over year. Revenues are projected to reach $1.48 billion, increasing 4.2% from the same quarter last year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Prior to a company's ear ...

Core Viewpoint - Hologic, Inc. reported adjusted earnings per share (EPS) of $1.03 for Q2 fiscal 2025, matching the previous year's figure and exceeding the Zacks Consensus Estimate by 0.9% [1]. Financial Performance - Revenues for the quarter totaled $1.01 billion, a decrease of 1.2% year over year, but surpassed the Zacks Consensus Estimate by 0.3% [2]. - The company experienced a GAAP loss per share of 8 cents, a significant improvement from a loss of 72 cents in Q2 fiscal 2024 [1]. Revenue Breakdown - U.S. revenues fell 1.9% year over year to $744.9 million, missing projections [3]. - International revenues increased by 0.8% year over year to $260.4 million, exceeding expectations [3]. Segmental Revenue Analysis - **Diagnostics**: Revenues increased by 0.8% year over year to $453.6 million, with a 4.5% increase excluding COVID-19 revenues [4]. - **Molecular Diagnostics**: Revenues of $326 million increased by 1.7% at constant exchange rates, aligning with projections [5]. - **Breast Health**: Revenues decreased by 7.4% year over year to $356.2 million, attributed to lower sales of mammography equipment [6]. - **GYN Surgical**: Revenues grew by 4.2% year over year to $162.5 million, surpassing expectations [7]. - **Skeletal Health**: Revenues declined by 21.8% year over year to $33 million, exceeding projections [8]. Operational Metrics - Adjusted gross margin increased by 40 basis points to 61.1%, while adjusted operating margin contracted by 40 basis points to 30% [9]. Cash and Debt Position - Cash and cash equivalents at the end of Q2 fiscal 2025 were $1.43 billion, down from $1.78 billion at the end of Q1 [10]. - Total long-term debt was $2.52 billion, slightly down from $2.53 billion in the previous quarter [10]. Future Outlook - For fiscal 2025, the company reiterated its revenue outlook of $4.05-$4.10 billion, indicating a year-over-year increase of 0.5%-1.7% [11]. - Adjusted EPS is now projected to be between $4.15 and $4.25, reflecting a downward revision from earlier estimates [12]. - For Q3 fiscal 2025, revenues are expected to be between $1 billion and $1.01 billion, suggesting a year-over-year decrease [12]. Market Context - The company’s performance has been impacted by a challenging economic environment, including tariff pressures and geopolitical conditions [14]. - Despite the challenges, Diagnostics revenues showed strength due to consistent demand in specific assay markets [15].

Kadant (KAI) Q1 2025 Earnings Call April 30, 2025 11:00 AM ET Company Participants Michael McKenney - Executive VP & CFOJeffrey Powell - President, Chief Executive Officer and DirectorGary Prestopino - Managing Director Conference Call Participants Ross Sparenblek - Equity Research AnalystKurt Yinger - Associate Vice President, Research AnalystWalter Liptak - Industry Analyst Operator Please be advised that today's conference is being recorded. I would like now to turn the conference over to Michael McKinne ...

Kadant (KAI) Q1 2025 Earnings Call April 30, 2025 11:00 AM ET Speaker0 Please be advised that today's conference is being recorded. I would like now to turn the conference over to Michael McKinney, Executive Vice President and Chief Financial Officer. Please go ahead, sir. Speaker1 Thank you, Michelle. Good morning, everyone, and welcome to Cadence first quarter twenty twenty five earnings call. With me on the call today is Jeff Powell, our President and Chief Executive Officer. Before we begin, let me read ...

Forum Energy Technologies (FET) is set to report first-quarter earnings on May 2, before the opening bell.Let us analyze the factors that are expected to have influenced FET’s performance in the first quarter of 2025.Q1 Expectations for FETThe Zacks Consensus Estimate for Forum Energy’s earnings is pegged at 43 cents per share and that for revenues is pinned at $196.3 million. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)The Zacks Consensus Estimate for first-quarter 2025 earning ...